Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biota Scientific Management has received a $2.9m funding from the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), for the preclinical development of its lead product which is indicated as a treatment for Clostridium difficile (C difficile).
Subscribe to our email newsletter
Biota Scientific Management is a wholly subsidiary of an Australia-based anti-infective drug developer, Biota.
As part of this 5-year grant funding, the company expects to receive $830,287 in the first year.
Future payments to Biota are subject to satisfactory project progress and the availability of funding.